Back to News
Market Impact: 0.28
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Johnson & Johnson CFO Joe Wolk said the company sees a path to growth above its previously stated 5%-7% long-term range. The outlook is supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility, signaling potential upside to the company’s existing long-term growth framework.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
JNJ0.55
More News
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go